Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Cystoscopy × Clear all
NCT02700464 2021-05-04

The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma

Nucleix Ltd.

Phase NA Completed
680 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00052637 2013-10-23

Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer

Photocure

Phase 3 Completed
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡